Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.03.30.21254604: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Sera were tested for SARS-CoV-2 IgG using three high-throughput commercial assays: Abbott Architect SARS-CoV-2 IgG (IgG targeting the N-protein; qualitative result only) [18], Abbott Architect SARS-CoV-2 IgG II Quant (IgG targeting the RBD-region of the S-protein; quantitative result) [18], and DiaSorin Liaison (trimeric S-protein assay targeting the S1/S2 regions of the S-protein; quantitative result) [19]. Abbott Architectsuggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_0…SciScore for 10.1101/2021.03.30.21254604: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Sera were tested for SARS-CoV-2 IgG using three high-throughput commercial assays: Abbott Architect SARS-CoV-2 IgG (IgG targeting the N-protein; qualitative result only) [18], Abbott Architect SARS-CoV-2 IgG II Quant (IgG targeting the RBD-region of the S-protein; quantitative result) [18], and DiaSorin Liaison (trimeric S-protein assay targeting the S1/S2 regions of the S-protein; quantitative result) [19]. Abbott Architectsuggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_019328)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:The principal limitation in our findings is that they only demonstrate the production of vaccine-induced antibodies in response to mRNA COVID-19 vaccines and their quantification. Correlations of specific titre levels to protection or vaccine efficacy cannot be made as the study is not designed or powered for this purpose. As the BNT162b2 and mRNA-1273 vaccines are different products, it is difficult to comment on the difference in median titres seen for the same time points on the same assay (which was observed in general to be lower in the mRNA-1273 group, despite a higher proportion of COVID-19 recovered individuals). This may reflect differing median ages of the two groups or alternatively be reflective of responses to varying vaccine products which is an artifact that could be corrected with an international standard for COVID-19 serology.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
